Medical Tidbits,Medtronic Initiates Global Study of Minimally Invasive Technology to Aid Lung Cancer Diagnosis

FDA Approvals, Jobs from the medical field

research

DUBLIN – September 22, 2015 – Committed to reducing lung cancer morbidity around the world, Medtronic’s (NYSE: MDT) Minimally Invasive Therapies Group recently launched a 2,500-patient, international study to assess real-world impact of its superDimension(TM) navigation system. The Company developed the study to support and validate the superDimension system, which the Company hopes will become the global standard-of-care for obtaining lung tissue biopsies from the periphery of the lungs1read more

Bausch + Lomb and Nicox Announce FDA Acceptance of New Drug Application for Novel Glaucoma Candidate VESNEO™ (latanoprostene bunod)

LAVAL, Quebec and SOPHIA ANTIPOLIS, France, Sept. 22, 2015 /PRNewswire/ — Valeant Pharmaceuticals International, Inc.’s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. (NYSE Euronext Paris: COX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for VESNEO™ (latanoprostene bunod ophthalmic solution 0.024%), an intraocular pressure (IOP) lowering single-agent eye drop dosed once daily, for patients with open angle glaucoma or ocular hypertension. If approved, VESNEO will be the first nitric oxide donating prostaglandin receptor agonist available for the above indication. read more

Takeda to Highlight Ixazomib Clinical Development Program at Upcoming International Myeloma Workshop

ROME–(EON: Enhanced Online News)–Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it will highlight the ixazomib clinical development program during multiple poster sessions at the upcoming 15th International Myeloma Workshop (IMW 2015) to be held in Rome, Italy, from September 23 to 26, 2015. read more

Praxair Prices $750 Million Notes

DANBURY, Conn.–(BUSINESS WIRE)–Praxair, Inc. (NYSE:PX) has priced $300 million of 2.25% notes due September 24, 2020 and $450 million of 3.20% notes due January 30, 2026. The notes are being offered under its shelf registration statement filed with the U.S. Securities and Exchange Commission. The offering is led by Citigroup Global Markets Inc., Deutsche Bank Securities Inc., HSBC Securities (USA) Inc. and Mitsubishi UFJ Securities (USA), Inc. read more

TransEnterix Acquires the ALF-X Surgical Robotic System

RESEARCH TRIANGLE PARK, N.C. & MILAN–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, announced today that it has acquired the surgical robotics division of SOFAR S.p.A., an Italian health care company, in a cash and stock transaction with total consideration of $99.8 million. SOFAR has developed the TELELAP ALF-X® advanced robotic system for minimally invasive surgery, which has an active CE Mark. read more

Impax Receives FDA Approval for Generic Version of Testred® C-III (Methyltestosterone Capsules, USP), 10 mg  

HAYWARD, Calif., Sept. 22, 2015 /PRNewswire/ — Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.S. Food and Drug Administration (FDA) has approved its generic version of Testred Capsules 10 mg. read more

Subscribe today for leading medical news and career advice from top  medical recruiters!

Subscribe today for leading medical news and career advice from top medical recruiters!

 

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.